Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

PURPOSE: Following promising responses to the DNA methyltransferase (DNMT) inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) combined with tetrahydrouridine (THU) in phase 1 testing, we initiated a non-randomized phase 2 study to assess response to this combination in patients with advanced solid tumor ty...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Chemother Pharmacol
Hoofdauteurs: Coyne, Geraldine O.’Sullivan, Wang, Lihua, Zlott, Jennifer, Juwara, Lamin, Covey, Joseph M., Beumer, Jan H., Cristea, Mihaela C., Newman, Edward M., Koehler, Stephen, Nieva, Jorge J., Garcia, Agustin A., Gandara, David R., Miller, Brandon, Khin, Sonny, Miller, Sarah B., Steinberg, Seth M., Rubinstein, Larry, Parchment, Ralph E., Kinders, Robert J., Piekarz, Richard L., Kummar, Shivaani, Chen, Alice P., Doroshow, James H.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer Berlin Heidelberg 2020
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188725/
https://ncbi.nlm.nih.gov/pubmed/32314030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04073-5
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items